# OnCo record revel (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/revel/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "revel", "NCT01168973" ;
  schema:name "REVEL"@en ;
  schema:description "Adding an antibody against the VEGF receptor to second-line chemotherapy added about six weeks of life: enough for a licence, not enough for NICE."@en ;
  schema:url <https://onco.cc/trials/revel/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01168973>, <https://doi.org/10.1016/S0140-6736(14)60845-X>, <https://www.nice.org.uk/guidance/ta403> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-squamous-cell-carcinoma/>, <https://onco.cc/cancers/lung-adenocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:trials <https://onco.cc/trials/lume-lung-1/>, <https://onco.cc/trials/lung-map-s1800a/> .